Clinical Trial Update: Study of Nivolumab-Ipilimumab and cfDNA in Lung Cancer [Phase 2]

View source ↗

Summary

Phase 2 study evaluating the combination of nivolumab and ipilimumab with circulating tumor DNA assessment in non-small cell lung cancer was terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: University Health Network, Toronto | Conditions: Non Small Cell Lung Cancer | Phase 2 | Status: TERMINATED